ResMed (RMD) : Traders are bullish on ResMed (RMD) as it has outperformed the S&P 500 by a wide margin of 7.56% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.76%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.82% in the last 1 week, and is up 8.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 4% and the 50-Day Moving Average is 10.08%. ResMed (NYSE:RMD): On Fridays trading session , Opening price of the stock was $70.5 with an intraday high of $70.71. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $70.16. However, the stock managed to close at $70.42, a loss of 0.13% for the day. On the previous day, the stock had closed at $70.51. The total traded volume of the day was 662,868 shares.
The company Insiders own 2.54% of ResMed shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -31.51% . Institutional Investors own 60.13% of ResMed shares. During last six month period, the net percent change held by insiders has seen a change of -22.34%. Also, Jefferies maintains its view on ResMed (NYSE:RMD) according to the research report released by the firm to its investors. The shares have now been rated Hold by the stock experts at the ratings house. Jefferies raises the price target from $56 per share to $60 per share on ResMed . The rating by the firm was issued on July 29, 2016.
ResMed Inc. is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories. It produces continuous positive airway pressure, variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape, AirSense 10 Elite, AirSense 10 CPAP, S9 VPAP S, S9 VPAP ST, S9 VPAP Adapt, S9 VPAP ST-A, S9 VPAP COPD and AirCurve 10 V Auto, among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX, Swift FX for Her, Mirage FX for Her, Pixi Pediatric Mask, Quattro FX for Her, Swift FX Bella, Swift FX Nano, AirFit N10 and Apnealink Air.